[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650329":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":52,"responsibleParty":69,"collaborators":31,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":31,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":31,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":31,"overallStatus":91,"whyStopped":31,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"The 95th Hospital of Putian，Putian, Fujian, China","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Mitochondrial Disease Experimental Group","EXPERIMENTAL","This prospective study aims to evaluate the effect of 12 week CoQ10 supplementation (300 mg\u002Fday) on liver fat content (assessed by FibroTouch CAP) in MDM patients with m.3243A\\>G mutation.",[13],"Drug: Coenzyme Q10 (drug)",{"label":15,"type":16,"description":17,"interventionNames":18},"Healthy Control Group","PLACEBO_COMPARATOR","Only undergo baseline assessments without intervention. Maintain the patient's original hypoglycemic treatment regimen unchanged.\n\nAvoid using medications that may affect mitochondrial function (e.g., minimize or switch metformin and statins if possible).\n\nDo not add other medications or supplements with antioxidant or mitochondrial protective effects during the study period.",[19],"Other: Only undergo baseline assessments without intervention.",{"label":21,"type":22,"description":23,"interventionNames":24},"Type 1 Diabetes Mellitus Control Group","ACTIVE_COMPARATOR","Maintain the patient's original hypoglycemic treatment regimen unchanged. Avoid using medications that may affect mitochondrial function (e.g., minimize or switch metformin and statins if possible).\n\nDo not add other medications or supplements with antioxidant or mitochondrial protective effects during the study period.",[19],[26,32,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Coenzyme Q10 (drug)","This prospective study aims to evaluate the effect of 12 week CoQ10 supplementation (300 mg\u002Fday) on liver fat content (assessed by FibroTouch CAP) in MDM patients with m.3243A\\>G mutation. An exploratory case control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls.",[9],null,{"type":6,"name":33,"description":33,"armGroupLabels":34,"otherNames":31},"Only undergo baseline assessments without intervention.",[15],{"type":6,"name":33,"description":33,"armGroupLabels":36,"otherNames":31},[21],[38],{"name":39,"affiliation":40,"role":41},"Rongfeng zhu","The 95th Hospital of Putian, Fujian , China","STUDY_CHAIR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":31,"email":47},"Jing Lin","CONTACT","+8615160238247","564310896@qq.com",{"name":49,"role":45,"phone":50,"phoneExt":31,"email":51},"Xuebai Chen","+8618760590880","Chenxuebai@126.com",[53],{"facility":54,"status":31,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"The 95th hospital of Putian","Putian","Fujian","351100","China","CN",{"type":61,"coordinates":62},"Point",[63,64],119.01028,25.43944,{"lat":64,"lon":63},[67],{"name":68,"role":45,"phone":50,"phoneExt":31,"email":51},"The Scientific Research and Education Department",{"type":70,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100650329","coq10-effects-on-mdm-liver-fat-via-fibrotouchi-100650329",false,"NCT07748130","CoQ10 Effects on MDM Liver Fat Via FibroTouchI.","The Effect of Coenzyme Q10 on Quantitative Changes in Hepatic Fat in Patients With Mitochondrial Diabetes","1\\. Mitochondrial Diabetes Group\n\nInclusion Criteria:\n\n1. Confirmed as a carrier of the mitochondrial DNA m.3243A\\>G mutation through genetic testing;\n2. Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria);\n3. Aged between 18 and 70 years;\n4. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 or type 2 diabetes (not caused by mitochondrial gene mutations);\n2. Comorbid with viral hepatitis, drug-induced hepatitis, alcoholic liver disease, Wilson's disease, or other specific diseases that can lead to fatty liver;\n3. Severe cardiac, pulmonary, or renal insufficiency;\n4. Pregnant or lactating women;\n5. Having used coenzyme Q10 or other mitochondrial-targeted drugs within the past 3 months;\n6. Having contraindications to MRI examination;\n7. Having experienced infection, surgery, or major trauma within the past 4 weeks.\n\nWithdrawal\u002FDropout Criteria:\n\n1. The subject withdraws informed consent;\n2. The occurrence of serious adverse events;\n3. Loss to follow-up;\n4. Medication adherence that continued participation in \\\u003C 80%;\n5. The researcher believes the study is not in the best interest of the subject. 2. Type 1 Diabetes Control Group\n\nInclusion Criteria:\n\n1. Meeting the diagnostic criteria for type 1 diabetes, with positive islet autoantibodies (GAD, IA-2, ICA, etc.);\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group. 3. Healthy Adult Control Group\n\nInclusion Criteria:\n\n1. No history of diabetes, with fasting blood glucose \\\u003C 5.6 mmol\u002FL and HbA1c \\\u003C 5.7%;\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group.",true,"ALL","18 Years","70 Years",{"count":83,"type":84},30,"ESTIMATED","INTERVENTIONAL",[87],"NA","Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg\u002Fday) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.",[90],"Mitochondrial Diabetes","NOT_YET_RECRUITING","2026-07-31",{"date":94,"type":95},"2026-08-05","ACTUAL",{"date":97,"type":84},"2026-09",{"date":99,"type":84},"2027-12",{"name":5,"class":6},1]